Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Katrina Sophia Pedersen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2793-6901; OpenAlex author ID A5001261934. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 14

  1. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  2. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  3. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac237↗
  4. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Co-author DOI 10.1158/1078-0432.ccr-23-1405↗
  5. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  6. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  7. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  8. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.11.06↗
  9. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Co-author DOI 10.1093/carcin/bgy072↗
  10. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  11. BRCA2‐associated pancreatic cancer and current screening guidelines First author DOI 10.1002/cncr.29447↗
  12. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Co-author DOI 10.1007/s10637-015-0246-2↗
  13. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Co-author DOI 10.1038/ejhg.2010.198↗
  14. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. Co-author DOI 10.1371/journal.pone.0018223↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Wang‐Gillam · 8 shared papers, 2015–2025 · strength 1.05
  2. Benjamin R. Tan · 7 shared papers, 2020–2025 · strength 0.99
  3. Kian‐Huat Lim · 7 shared papers, 2020–2025 · strength 0.99
  4. Patrick M. Grierson · 4 shared papers, 2020–2025 · strength 0.61
  5. Robert R. McWilliams · 6 shared papers, 2011–2023 · strength 0.48
  6. David G DeNardo · 3 shared papers, 2022–2025 · strength 0.44
  7. William G. Hawkins · 3 shared papers, 2022–2023 · strength 0.38
  8. Albert Craig Lockhart · 3 shared papers, 2020–2023 · strength 0.34
  9. Brett H. Herzog · 2 shared papers, 2022–2023 · strength 0.24
  10. Jad I. Belle · 2 shared papers, 2022–2023 · strength 0.24
  11. Feng Gao · 2 shared papers, 2022–2023 · strength 0.24
  12. John M. Baer · 1 shared paper, 2025 · strength 0.19
  13. Gloria M. Petersen · 4 shared papers, 2011–2018 · strength 0.17
  14. Sapana Bansod · 1 shared paper, 2023 · strength 0.16
  15. Channing J. Der · 1 shared paper, 2023 · strength 0.16
  16. Kari G. Rabe · 3 shared papers, 2011–2018 · strength 0.14
  17. Michael Charles Roach · 1 shared paper, 2023 · strength 0.14
  18. Todd A. DeWees · 1 shared paper, 2023 · strength 0.14
  19. Hyun Jee Kim · 1 shared paper, 2023 · strength 0.14
  20. Lauren E. Henke · 1 shared paper, 2023 · strength 0.14
  21. Parag Jitendra Parikh · 1 shared paper, 2023 · strength 0.14
  22. Shahed Nicolas Badiyan · 1 shared paper, 2023 · strength 0.14
  23. Ryan C Fields · 1 shared paper, 2023 · strength 0.14
  24. Chet W. Hammill · 1 shared paper, 2023 · strength 0.14
  25. Wei Zheng · 2 shared papers, 2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.